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Chronic productive cough is a common symptom in patients with bronchiectasis that is associ-
ated with a reduction in health-related quality of life (QOL). Bronchopulmonary hygiene phys-
ical therapy (BHPT) is widely prescribed for patients with bronchiectasis, although the
evidence for its efficacy is limited. We set out to prospectively evaluate the impact of BHPT
on health-related QOL in patients with non-cystic fibrosis bronchiectasis.
We assessed cough symptoms (0e100 mm visual analogue scale; VAS) and cough-related QOL
in 53 patients with stable non-cystic fibrosis bronchiectasis at baseline and >4 weeks after
outpatient-based BHPT. Cough specific health status was assessed with the Leicester Cough
Questionnaire (LCQ; total score range 3e21, higher scores representing better QOL).
All patients with bronchiectasis complained of cough as the major symptom and had mean
(SEM) FEV1 of 2.1 (0.1) L. Cough-related health status was reduced at baseline; mean (SEM)
LCQ score 14.3 (0.6). There were significant improvements in cough symptoms (mean cough
VAS before 43.3 (3.6) vs after 27.5 (3.1); mean difference 15.8; 95% CI of difference
9.6e22; p< 0.0001) and cough-related health status after BHPT (mean LCQ total score before
14.2 vs after 17.3; mean difference 3.1; 95% confidence interval of difference 2.4e3.9;
p< 0.001). A significant improvement was seen in all LCQ health-related domains (physical,
psychological and social; all p< 0.001).
Our findings suggest that bronchopulmonary hygiene physical therapy can lead to a signifi-
cant improvement in cough-related quality of life.
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12Bronchiectasis is characterised by permanent dilatation of
the bronchi and impaired clearance of airway secretions.
A wide range of immunological, infective and genetic
conditions can lead to the development of bronchiectasis
but a substantial proportion of cases is unexplained.
Patients with bronchiectasis commonly present with
a chronic productive cough and recurrent chest infec-
tions.1,2 Progressive decline in lung function and deteriorat-
ing functional capacity is frequently seen and patients can
suffer significant physical and psychological morbidity that
leads to impaired health-related QOL.3,4
There is a paucity of effective therapeutic agents for
patients with bronchiectasis. Bronchopulmonary hygiene
physical therapy (BHPT) is the mainstay therapy for most
patients and is widely prescribed as a prophylactic and
therapeutic intervention. BHPT comprises patient educa-
tion and a range of physical techniques that aid clearance
of airway secretions.5 Despite its routine use in both acute
exacerbations and chronic non-cystic fibrosis (CF) bronchi-
ectasis, the evidence for its efficacy is limited. BHPT may
reduce sputum volume and increase clearance but there
are no studies investigating the impact of BHPT on health-
related QOL.6e8 A recent Cochrane database systematic
review identified few clinical trials investigating BHPT in
non-CF bronchiectasis and most of these contained small
numbers of patients.9 This review concluded that there
was insufficient evidence to support the use of BHPT in
non-CF bronchiectasis. The aim of our study was to investi-
gate the effect of BHPT on health-related QOL in patients
with stable non-CF bronchiectasis.
Methods
Patients
Consecutive patients diagnosed with bronchiectasis were
identified from those attending adult respiratory outpatient
clinics. Bronchiectasis was diagnosed if patients had
characteristic clinical features and typical radiological
appearance of bronchiectasis (chest radiograph and/or
high resolution computerised tomography scan; HRCT
scan).10 All but four patients had bronchiectasis confirmed
on HRCT. Only clinically stable patients with no significant
change in symptoms in the preceding 4 weeks were
recruited. No patient had BHPT previously. Patients with
radiological appearance of traction bronchiectasis and
recent respiratory tract infection (<8 weeks) were ex-
cluded. Localised bronchiectasis was defined as disease
confined to a single pulmonary lobe.
Leicester Cough Questionnaire (LCQ)
Heath status was assessed with the LCQ which is a 19 item,
self-completed, cough specific health-related QOL ques-
tionnaire. 11 The LCQ has been extensively validated and
has been shown to be valid, reproducible and responsive.
The LCQ has three domains: physical, psychological and
social (domain score range 1e7; higher scoreZ better
QOL). The overall QOL scores range from 3 to 21, 21 beingtotal score is 1.3.
Protocol
All patients with bronchiectasis were referred for out-
patient BHPT. The LCQ and cough symptom severity visual
analogue score (0e100 mm; 100 mm worst cough) were
administered at initial assessment and >4 weeks later at
a follow-up visit. BHPT comprised two sessions at least 2
weeks apart.
Session 1 (1 h)
 General assessment of condition, symptoms, social
circumstances and medications.
 Introduction to physiotherapy and aims of treatment.
 Education about disease and self-management
rationale.
 Selection of appropriate chest clearance techniques to
establish a home programme from the following:
- Active cycle of breathing techniques (ACBT)
- Autogenic drainage (AD)
- Flutter
- Modified postural drainage (MPD)
- Breathing retraining advice (BR)
- Cough control techniques (CC)
 Written information given to reinforce education,
management and physiotherapy techniques.
Session 2 (30 mine1 h)
 Progress review assessing compliance with physiother-
apy manoeuvres.
 Refine self-management as necessary and discuss any
concerns.
 Reinforce aims of physiotherapy including short and
long-term goals.
 Holistic advice as indicated: coping strategies for
breathlessness, breathing pattern correction, monitor-
ing exercise levels.
Analysis
Data is presented as mean (SEM: standard error of mean).
Paired t-tests were used to compare VAS and QOL scores
before and after BHPT. The relationship between FEV1
and change in health status was assessed with Pearson’s
correlation coefficient. Graphpad Prism (Graphpad soft-
ware Inc) and Minitab software were used for analysis.
The study protocol was approved by the local research
ethics committee and all subjects gave informed consent.
Results
Fifty-three patients met the inclusion criteria during the
study period (Table 1). No patient declined participation or
withdrew from the study. The cause of the bronchiectasis
was idiopathic (nZ 39), previous non-tuberculous infection
(nZ 10), previous tuberculosis (nZ 2), allergic broncho-
pulmonary aspergillosis (nZ 1) and immunoglobulin
Table 1 Patient characteristics
n 53
Female 30 (55%)
Mean age, years 67 (1.4)
Mean duration of cough, years 8 (2.8)
Non-productive cough 8 (15%)
Localised Bronchiectasis 6 (11%)
Mean FEV1 2.1 (0.1)
Current smokers 4 (7.5%)
Ex smokers 20 (37%)
Pseudomonas colonisation 2 (3%)
Data expressed as n(%): number; Mean (SEM): standard error of
mean; FEV1Z forced expiratory volume in 1 s, litres; localised
bronchiectasisZ bronchiectasis confined to one pulmonary
lobe; Pseudomonas colonisationZ>2 positive Pseudomonas
sputum cultures; and ex-smokerZ>10 pack year smoking
history.
Figure 1 Cough VAS scores before and after bronchopulmonary
hygiene physical therapy. Bars representmean (SEM). *p< 0.0001.
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45 (85%) had a productive cough (Table 1). The mean
(SEM) duration between administration of the first and
second LCQ was 8 (1.6) weeks. The combinations of
BHPT techniques administered are presented in Table 2.
At the follow-up visit, all patients reported administering
their BHPT regime at least once a day.
There was a significant reduction in cough VAS after
BHPT. The mean (SEM) cough VAS before and after BHPT
were 43 (4) and 27 (3); mean difference 16; 95%
confidence interval of difference 10e22; p< 0.0001
(Fig. 1). Health-related QOL was impaired in patients
with bronchiectasis at baseline; mean (SEM) total LCQ
score 14.3 (0.6) (normalZ 21, Fig. 2). There were reduc-
tions in physical, psychological and social health domain
scores of the LCQ at baseline (Fig. 2). A significant
improvement was seen in cough specific QOL after BHPT;
total LCQ score before 14.3 vs 17.4 after BHPT; mean dif-
ference 3.0; 95% confidence interval of difference
2.3e3.7; p< 0.0001; Fig. 2. A significant improvement
was seen in all LCQ health domains with BHPT (Fig. 2).
Forty-eight (90%) patients had an improvement in health
status greater than the LCQ minimal important clinical
difference (LCQ score> 1.3).Table 2 Bronchopulmonary hygiene therapy regimes
Physiotherapy techniques Number of patients
EDþ ACBTþ AD 25
EDþ ACBT 10
EDþ ACBTþ ADþ BR 9
EDþ ACBTþ BR 2
EDþ ACBTþMPD 2
EDþ ACBTþMPDþ BR 1
EDþ ACBTþ ADþMPDþ BR 1
EDþ ACBTþ ADþMPD 1
EDþ ACBTþ ADþ CC 1
EDþ ACBTþ ADþ CCþ BR 1
ACBT: activated cycle of breathing technique; AD: autogenic
drainage; BR: breathing retraining advice; ED: education;
MPD: Modified postural drainage; and CC: cough control
techniques.A significant improvement in cough specific health-related
QOL was seen after BHPT in male patients pZ 0.017; female
patients pZ 0.0014; patients with localised bronchiectasis
pZ 0.02; generalised bronchiectasis pZ 0.001; non-smokers
pZ 0.004; current or ex smokers pZ 0.003. There were no
significant differences in QOL improvements of males (mean
change in total LCQ 3.1) compared with females (3.1;
pZ 0.9) nor in the LCQ domains (pZ 0.4e0.6). There was
no relationshipbetweenbaselineFEV1andchange inLCQtotal
score after BHPT (rZ 0.2; pZ 0.2). No adverse effects of
BHPTwere reported by patients in this study.
Discussion
We have shown that BHPT leads to a reduction in cough
symptoms and an improvement in health-related QOL in
patients with non-CF bronchiectasis. This is the largest
study of BHPT in non-CF bronchiectasis and the first to
assess the impact of BHPT on health-related QOL. The
improvement in QOL was large, greater than the LCQ
minimal important clinical difference and was seen in
most patients.
Most patients with bronchiectasis have a productive
cough which can be a distressing symptom associated with
significantly impaired quality of life.13,14 The mechanism of
cough is unclear but is thought to result from airway inflam-
mation and heightened cough reflex sensitivity.15 In a recent
report, heightened cough reflex sensitivity in patients with
bronchiectasis was associated with increased cough symp-
toms and reduced health-related QOL.16 Pooling of airway
secretion in bronchiectasis is thought to be an important
factor in the development of airway inflammation, height-
ened cough reflex sensitivity, recurrent respiratory tract
infections and exacerbations. Current therapy for bronchi-
ectasis aims to minimise pooling of airway secretions and
reducing airway inflammation. BHPT is widely used for
patients with stable bronchiectasis but evidence for its
efficacy is limited. There are a few published studies of
Figure 2 Cough specific health-related quality of life before and after bronchopulmonary hygiene physical therapy; (A) overall
QOL and (B) physical, psychological and social domains. Leicester Cough Questionnaire (LCQ: range 3e21; high scoreZ better qual-
ity of life); LCQ domain score range 1e7 (high scoreZ better quality of life); Solid bars: baseline; Open bars: after BHPT; mean
(SEM); and *p< 0.0001.
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only single sessions of BHPT and none have evaluated its
impact on QOL. A large meta-analysis of chest physiother-
apy in cystic fibrosis patients with bronchiectasis reported
that standard physical therapy did aid sputum expectora-
tion compared to no treatment.5 In non-CF bronchiectasis,
a recent Cochrane database review concluded that there
was insufficient published evidence to support the use of
BHPT and also suggested that future studies should assess
health-related QOL.17 BHPT can be labour intensive, expen-
sive, inconvenient for some patients, associated with
potential adverse effects, hence evaluation of this therapy
in bronchiectasis is needed.18,19 Our data suggests that
BHPT can significantly reduce in cough symptoms and result
in a large improvement in health status without adverse
effects.
There are limitations to this study most notably the lack
of a control group. The placebo effect is common in clinical
trials of patients with cough but this is usually more
prominent in patients with acute cough. In our study, all
patients had a stable chronic cough of longstanding dura-
tion, many of whom had unsuccessful trials of other
therapies previously. It is possible that some patients may
not have been compliant with BHPT since we did not
measure compliance objectively. Compliance is difficult
to assess in this setting but a compliance check at the
follow-up visit, although subjective, indicated that patients
administered at least one session of BHPT daily and this was
associated with an improvement in symptoms and QOL.
Another limitation is that only subjective outcome mea-
sures were assessed. The patients recruited in this study
had mild to moderate lung function impairment and low
rates of Pseudomonas colonisation so we cannot be sure
that the quality of life benefits of BHPT extend to patients
with more severe bronchiectasis. Our findings should be
considered preliminary and provide a platform for a larger
randomised controlled trial. Further studies should assess
long-term benefits, effects on lung function, exacerba-
tions, cost effectiveness and incorporate objective out-
come measures such as cough frequency monitoring and
cough reflex sensitivity measurements.We tailored BHPT individually for patients according to
symptoms, practicability and acceptability. BHPT consists
of several components and the relative efficacy of each
component is not known or how they compare to education
alone. We were unable to carry out this sub-analysis since
the prescribed BHPT program often comprised of several
components at one sitting. Further study of the efficacy of
BHPT components and determination of optimal number of
sessions would be valuable to design a clinically cost
effective program. The effectiveness of BHPT in bronchi-
ectasis according to aetiology also deserves further
investigation.
In conclusion, BHPT is a safe, well-tolerated and accept-
able form of therapy for patients with non-CF stable
bronchiectasis that leads to an improvement in cough
symptoms and health-related quality of life. Further stud-
ies are required to confirm our findings in a randomised
controlled trial and determine the optimum duration of
therapy and efficacy of BHPT components.Acknowledgement
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